| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26,9 k € | -55.6% | 60,5 k € | 0.0% | 60,5 k € | +19.1% | 50,8 k € | -28.4% | 71,0 k € | -9.5% | 78,5 k € | +0.1% | 78,4 k € | 0.0% | 78,4 k € | -12.5% | 89,7 k € | 0.0% | 89,7 k € | 0.0% | 89,7 k € | |
| Gross margin | 18,8 k € | -62.2% | 49,7 k € | +4.4% | 47,6 k € | +6.7% | 44,6 k € | -29.8% | 63,5 k € | -10.0% | 70,6 k € | +1.0% | 69,9 k € | -10.8% | 78,3 k € | -6.0% | 83,3 k € | -1.2% | 84,2 k € | -4.3% | 88,0 k € | |
| EBITDA | 18,4 k € | -62.7% | 49,3 k € | +4.3% | 47,2 k € | +6.8% | 44,3 k € | -29.5% | 62,8 k € | -10.6% | 70,2 k € | +1.8% | 69,0 k € | -10.9% | 77,4 k € | -6.6% | 82,9 k € | -1.2% | 83,9 k € | -4.4% | 87,7 k € | |
| Operating profit | 18,4 k € | +189.9% | -20,4 k € | +9.0% | -22,5 k € | +11.7% | -25,5 k € | -266.1% | -7,0 k € | -1447.5% | 516,0 € | +149.8% | -1,0 k € | -114.0% | 7,4 k € | -42.5% | 12,9 k € | -7.0% | 13,9 k € | -21.6% | 17,7 k € | |
| Profit/loss | 18,3 k € | +189.3% | -20,5 k € | +22.1% | -26,3 k € | +1.0% | -26,6 k € | -141.3% | -11,0 k € | -125.3% | -4,9 k € | +42.3% | -8,5 k € | -993.9% | -775,0 € | -124.7% | 3,1 k € | +69.6% | 1,8 k € | +700.0% | 231,0 € | |
| Equity | -68,8 k € | +21.0% | -87,1 k € | -30.8% | -66,6 k € | -65.2% | -40,3 k € | -193.5% | -13,7 k € | -404.3% | -2,7 k € | -225.9% | 2,2 k € | -79.7% | 10,6 k € | -6.8% | 11,4 k € | +37.9% | 8,3 k € | +28.8% | 6,4 k € | |
| Total assets | 247,9 k € | -5.6% | 262,5 k € | -16.6% | 314,6 k € | -12.3% | 358,7 k € | -13.2% | 413,5 k € | -14.0% | 480,7 k € | +36.6% | 351,9 k € | -16.1% | 419,3 k € | -15.9% | 498,3 k € | -34.9% | 765,2 k € | -7.9% | 830,5 k € | |
| Cash | 42,0 € | +366.7% | 9,0 € | -84.2% | 57,0 € | — | 0,0 € | -100.0% | 231,0 € | +19.7% | 193,0 € | -71.7% | 683,0 € | -37.0% | 1,1 k € | +131.1% | 469,0 € | -46.6% | 879,0 € | |||
| Debts | 316,7 k € | -9.4% | 349,6 k € | -8.3% | 381,3 k € | -4.5% | 399,1 k € | -6.6% | 427,3 k € | -11.6% | 483,4 k € | +38.2% | 349,8 k € | -14.4% | 408,6 k € | -16.1% | 486,9 k € | -35.7% | 757,0 k € | -8.1% | 824,1 k € | |
Source: Belgian Official Gazette
Private company with limited liability · Lubbeek · incorporated on 22/01/2014
Private company with limited liability with a balanced profile. Cash position rising (+366.7%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
| Unit no. | Name | Location |
|---|---|---|
| 2226736156 | beisol pharma kortenberg | Staatsbaan(LUB) 187, 3210 Lubbeek |
Beisol Pharma Kortenberg is a Private company with limited liability incorporated in 2014. Its main activity is: Location-bail de propriété intellectuelle et de produits similaires, à l’exception des œuvres soumises à copyright. Its registered office is in Lubbeek.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.